| 000 | 01907 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515205030.0 | ||
| 264 | 0 | _c20100331 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1528-4336 | ||
| 024 | 7 |
_a10.1310/hct1006-368 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNunes, Estevão P | |
| 245 | 0 | 0 |
_aMonotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). _h[electronic resource] |
| 260 |
_bHIV clinical trials _c |
||
| 300 |
_a368-74 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xadverse effects |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aDrug Resistance, Viral _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aPyrimidinones _xadministration & dosage |
| 650 | 0 | 4 |
_aRitonavir _xadministration & dosage |
| 650 | 0 | 4 |
_aSemen _xvirology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aViral Load _xdrug effects |
| 700 | 1 | _aSantini de Oliveira, Marilia | |
| 700 | 1 | _aMerçon, Monica | |
| 700 | 1 | _aZajdenverg, Roberto | |
| 700 | 1 | _aFaulhaber, Jose Claudio | |
| 700 | 1 | _aPilotto, José Henrique | |
| 700 | 1 | _aRibeiro, Jorge Eurico | |
| 700 | 1 | _aNorton, Michael | |
| 700 | 1 | _aSchechter, Mauro | |
| 773 | 0 |
_tHIV clinical trials _gvol. 10 _gno. 6 _gp. 368-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1310/hct1006-368 _zAvailable from publisher's website |
| 999 |
_c19504994 _d19504994 |
||